SRES 477119th CongressIn Committee

A resolution designating the first full week in May as "Tardive Dyskinesia Awareness Week".

Introduced: Oct 30, 2025

Sponsor: Sen. Mullin, Markwayne [R-OK] (R-Oklahoma)

Healthcare

Standard Summary

Comprehensive overview in 1-2 paragraphs

This Senate resolution designates the first full week of May as Tardive Dyskinesia Awareness Week to promote early detection, reduce stigma, and encourage routine screening for this antipsychotic medication side effect affecting approximately 800,000 Americans, 60% of whom remain undiagnosed despite available FDA-approved treatments.

Key Points

1Tardive dyskinesia causes uncontrollable facial and bodily movements as a side effect of prolonged antipsychotic medication use for conditions like schizophrenia and bipolar disorder.
2High-risk groups include individuals over 55, Black patients, women, and those with mood disorders or intellectual disabilities requiring antipsychotic treatment.
3The resolution emphasizes American Psychiatric Association guidelines mandating routine TD screenings to prevent undiagnosed cases that impair patients' social and emotional well-being.

Impact Areas

Patients prescribed antipsychotic medications for mental health conditionsHealthcare providers conducting TD screenings and treatment managementCare partners and families supporting individuals with undiagnosed tardive dyskinesia

Generated by legislative-analysis-v1 on Nov 5, 2025